{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:43Z","timestamp":1794047563796,"version":"4.8.0"},"reference-count":6,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2025.288338","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:25:21Z","timestamp":1782897921000},"page":"2205-2206","source":"Crossref","is-referenced-by-count":0,"title":["Introduction to the Review Series. Chronic myeloid leukemia in 2026"],"prefix":"10.3324","volume":"111","author":[{"given":"Jerald","family":"Radich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"90975","doi-asserted-by":"crossref","unstructured":"Jain AG, Dalgetty M, Cortes JE. Is there a best frontline therapy in chronic myeloid leukemia?. Haematologica. 2026; 111(7):2216-2226.","DOI":"10.3324\/haematol.2025.287813"},{"key":"90976","doi-asserted-by":"crossref","unstructured":"Krishnan V, Shyamsunder P, Ong ST. Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses. Haematologica. 2026; 111(7):2227-2243.","DOI":"10.3324\/haematol.2025.287767"},{"key":"90977","doi-asserted-by":"crossref","unstructured":"Cruz-Rodriguez N, Torres-Llanos Y, Deininger MW. Intrinsic cellular resistance to BCR::ABL1 inhibitors. Haematologica. 2026; 111(7):2244-2265.","DOI":"10.3324\/haematol.2025.287814"},{"key":"90978","doi-asserted-by":"crossref","unstructured":"Flynn KE, Atallah E. Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission. Haematologica. 2026; 111(7):2281-2290.","DOI":"10.3324\/haematol.2025.287766"},{"key":"90979","doi-asserted-by":"crossref","unstructured":"Oehler VG, Berman E, Huang IJ. Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing. Haematologica. 2026; 111(7):2266-2280.","DOI":"10.3324\/haematol.2025.288334"},{"key":"90980","doi-asserted-by":"crossref","unstructured":"Rea D. Prognostic factors in chronic myeloid leukemia: at diagnosis and for treatment-free remission. Haematologica. 2026; 111(7):2207-2215.","DOI":"10.3324\/haematol.2025.287756"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/14252\/80427","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/14252\/80428","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/14252\/80427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:14:35Z","timestamp":1794046475000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/14252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":6,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.288338","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}